These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 16278611)
1. Periodontal assessment of postmenopausal women receiving risedronate. Palomo L; Bissada NF; Liu J Menopause; 2005; 12(6):685-90. PubMed ID: 16278611 [TBL] [Abstract][Full Text] [Related]
2. The strength of association between systemic postmenopausal osteoporosis and periodontal disease. Mohammad AR; Brunsvold M; Bauer R Int J Prosthodont; 1996; 9(5):479-83. PubMed ID: 9108750 [TBL] [Abstract][Full Text] [Related]
3. Periodontal conditions in 70-year-old women with osteoporosis. Lundström A; Jendle J; Stenström B; Toss G; Ravald N Swed Dent J; 2001; 25(3):89-96. PubMed ID: 11813450 [TBL] [Abstract][Full Text] [Related]
4. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Ilter E; Karalok H; Tufekci EC; Batur O Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659 [TBL] [Abstract][Full Text] [Related]
6. Spinal bone density and tooth loss in a cohort of postmenopausal women. Mohammad AR; Bauer RL; Yeh CK Int J Prosthodont; 1997; 10(4):381-5. PubMed ID: 9484049 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951 [TBL] [Abstract][Full Text] [Related]
8. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280 [TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782 [TBL] [Abstract][Full Text] [Related]
11. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Tanriverdi HA; Barut A; Sarikaya S Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088 [TBL] [Abstract][Full Text] [Related]
12. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
14. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Dane C; Dane B; Cetin A; Erginbas M Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907 [TBL] [Abstract][Full Text] [Related]
15. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644 [TBL] [Abstract][Full Text] [Related]